Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21597911 | 0.98 | PIK3CD (0.63) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL22797789 | 0.89 | PIK3CD (0.54) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL27707181 | 0.87 | SLC6A2 (0.50) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL22797930 | 0.83 | PIK3CD (0.45) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL297266 | 0.79 | SLC6A4 (0.49) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9653066 | 0.79 | SLC6A2 (0.46) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL19701909 | 0.79 | PIK3CD (1.00) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL3740415 | 0.78 | SLC6A4 (0.48) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4913906 | 0.78 | SLC6A2 (0.42) | PIK3CDSLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL17043097 | 0.77 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2021-01-07 | — | — | US | disclosed |
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
| WO-2019243851-A1 | BRIDGED COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773090-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | PIK3CD 2063/4885SLC6A2 1197/4885SLC6A4 1162/4885 |
| US-20210002271-A1 | PHARMACEUTICAL COMPOUNDS | CHRM1, CHRM2, CHRM4 | PIK3CD 2063/4885SLC6A2 1197/4885SLC6A4 1162/4885 |
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | PIK3CD 2063/4885SLC6A2 1197/4885SLC6A4 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.